We know Teva is looking for acquisitions. Maybe acquiring Antares is part of their strategy. If so, it may date back to the time of Teva and Abbott settlement on Bio-t-gel. The discovery that Libigel reduces the risk of Cardiovascular events in post menopausal women (who are at risk) by at least 71% may be the center-piece of such a deal (if it exists).
ANI Pharmaceuticals (ANI merged with Bpax) acquiring 31 drugs FDA approved drugs from Teva for only $12.5 million and future portion of gross profits.
Teva buys Antares, thereby getting their territorial rights to Libigel, in addition to the rest of Antares portfolio.
ANI partners with Abbvie to co promote Libigel for North America and out-license Libigel to Abbvie for the rest of their territories. This is consistent with other co-promotion deal Abbvie has done.
The above scenario would actually explain the following:
1) Greg DeFilippis starts to work at Antares while apparently still working at Teva almost on the heels of the Biosante - Ani merger. (Was it done to facilitate a buyout of Antares by Teva?)
Quote: Greg DeFilippis' Experience
Senior Director, Business Alliances and Device Supply Chain Management Antares Pharma Inc. July 2013 – Present (7 months) Ewing, NJ
Director, Business Development Teva Pharmaceuticals August 2009 – Present (4 years 6 months)
2)Dr Snabes (lead investigator for Libigel)is hired by Abbvie immediately upon release from Biosante as Sr Director of Abbvie Men and Women's Health.
3) Abbvie website states they are focusing on Women's Health but are not looking for partnering opportunities in Women's Health and they are no longer focusing on Men's Health.
4) The only product in Abbvie's Women's Health portfolio is Elagolix yet they are hiring a Sr Director for Elagolix. (Now what is Snabes going to do? Libigel?)
5) The fact Bpax and Anip have not said squat about the significant discovery of the cardiovascular benefits for Libigel.
News 
Market Data 
Discover 
